Updated: 8th September 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
Understanding the EU MDR and UK MDR
Following the UK’s departure from the European Union, medical device manufacturers may need to comply with different regulatory requirements depending on where their devices are placed on the market.
The European Union is governed by Regulation (EU) 2017/745 on medical devices (EU MDR), while medical devices placed on the market in Great Britain are regulated under the UK Medical Devices Regulations 2002 (UK MDR 2002), as amended.
Although the two regulatory systems share many principles, they are no longer the same. Manufacturers need to consider differences in areas such as conformity assessment, regulatory representation, device registration, marking requirements and post-market surveillance.
The position is also different between Great Britain and Northern Ireland. Great Britain consists of England, Scotland and Wales and operates under the UK MDR 2002. Northern Ireland has separate arrangements under the Windsor Framework, with relevant EU medical device rules continuing to apply.
For manufacturers targeting both the EU and UK markets, the first step is therefore to understand which regulatory framework applies in each territory and where requirements can be aligned without assuming that compliance with one regime automatically demonstrates compliance with the other.
What is the EU MDR?
The EU Medical Device Regulation (Regulation (EU) 2017/745), commonly referred to as the EU MDR, establishes the regulatory framework for medical devices placed on the European Union market.
The EU MDR has applied since 26 May 2021 and replaced the previous Medical Devices Directive (93/42/EEC) and Active Implantable Medical Devices Directive (90/385/EEC), subject to transitional provisions for eligible legacy devices.
The Regulation establishes requirements covering the full medical device lifecycle, including:
- Medical device classification
- General Safety and Performance Requirements (GSPRs)
- Technical documentation
- Clinical evaluation and clinical investigations
- Quality management systems
- Conformity assessment and Notified Body involvement
- CE marking
- Economic operators, including EU Authorised Representatives and importers
- Unique Device Identification (UDI)
- Device registration and EUDAMED
- Post-market surveillance (PMS)
- Post-market clinical follow-up (PMCF)
- Vigilance and reporting
Manufacturers must demonstrate conformity with the applicable EU MDR requirements before placing a device on the EU market. Depending on the classification and characteristics of the device, this may require conformity assessment by an EU-designated Notified Body.
For manufacturers established outside the EU, an EU Authorised Representative must also generally be appointed before the device can be placed on the EU market.
Need an Introduction to the EU Medical Device Regulation?
This article focuses on the differences between the EU MDR and UK MDR for manufacturers operating across both markets. If you're looking for a complete overview of the EU Medical Device Regulation, including classification, conformity assessment, technical documentation, clinical evaluation, CE marking, post-market surveillance and economic operator requirements, read our Complete Guide to the EU Medical Device Regulation.
What is the UK MDR?
Medical devices placed on the market in Great Britain — England, Scotland and Wales — are currently regulated under the Medical Devices Regulations 2002 (SI 2002 No. 618), as amended, commonly referred to as the UK MDR 2002.
Unlike the EU MDR, the current Great Britain regulatory framework remains substantially based on requirements derived from the former EU medical device directives. The UK Government and MHRA are progressively reforming this framework through amendments to the UK MDR 2002.
The UKCA marking provides the domestic conformity assessment route for medical devices placed on the Great Britain market. Where third-party conformity assessment is required for UKCA marking, manufacturers must use a UK Approved Body.
However, manufacturers do not currently have to obtain UKCA marking simply because they wish to sell a medical device in Great Britain. Eligible CE-marked medical devices continue to be recognised under transitional arrangements.
Under the current arrangements:
- EU MDR-compliant general medical devices, including custom-made devices, can be placed on the Great Britain market until 30 June 2030.
- Eligible devices compliant with the former EU MDD or AIMDD can generally continue to be placed on the Great Britain market until the sooner of the expiry of the applicable certificate or 30 June 2028.
- Separate transitional arrangements apply to in vitro diagnostic medical devices.
Manufacturers placing medical devices on the Great Britain market must also comply with applicable UK-specific requirements. These include registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and, for manufacturers based outside the UK, appointment of a UK Responsible Person.
The UK regulatory framework is continuing to evolve, so manufacturers should consider both the requirements that apply today and forthcoming regulatory changes when developing their UK market access strategy.
Need an Introduction to UK Medical Device Regulations?
This article compares EU MDR and UK MDR requirements for manufacturers navigating both markets. If you're looking for a complete overview of UK medical device regulations, including UKCA marking, MHRA registration, UK Responsible Person requirements, classification and post-market surveillance, read our Complete Guide to UK Medical Device Regulations.
EU MDR vs UK MDR: Key Differences
Although the EU MDR and UK MDR share many underlying principles for medical device safety and performance, they are separate regulatory frameworks with different legal requirements, regulatory authorities and market access routes.
For manufacturers seeking access to both the European Union and Great Britain, understanding these differences is essential. The table below provides a practical comparison of the main requirements.
| Requirement | European Union | Great Britain |
|---|---|---|
| Regulatory framework | Regulation (EU) 2017/745 (EU MDR) | Medical Devices Regulations 2002 (UK MDR 2002), as amended |
| Regulator | National competent authorities operate within the EU regulatory framework | Medicines and Healthcare products Regulatory Agency (MHRA) |
| Product marking | CE marking | UKCA marking, with eligible CE-marked devices currently recognised under transitional arrangements |
| Conformity assessment body | EU-designated Notified Body where third-party assessment is required | UK Approved Body where third-party assessment is required for the UKCA route |
| Device classification | EU MDR classification system: Classes I, IIa, IIb and III | Current UK MDR classification system: Classes I, IIa, IIb and III for general medical devices |
| Regulatory representative | Non-EU manufacturers generally require an EU Authorised Representative | Manufacturers based outside the UK must appoint a UK Responsible Person |
| Technical documentation | Technical documentation must demonstrate conformity with the EU MDR | Technical documentation must demonstrate conformity with the applicable UK MDR requirements |
| Safety and performance requirements | EU MDR General Safety and Performance Requirements (GSPRs) | Applicable Essential Requirements under the current UK MDR |
| Clinical evidence | Clinical evaluation conducted in accordance with the EU MDR, including applicable requirements of Article 61 and Annex XIV | Clinical evidence must meet the applicable requirements of the UK MDR |
| Quality management | EU MDR establishes QMS requirements, with the extent of conformity assessment depending on the regulatory route and device | UK MDR conformity assessment routes include applicable quality system requirements |
| Device registration | EU registration requirements are increasingly implemented through EUDAMED under the EU MDR framework | Devices placed on the Great Britain market must be registered with the MHRA, subject to applicable requirements |
| UDI | EU MDR UDI requirements apply according to the relevant implementation timelines | The future GB regulatory framework includes development of enhanced device identification requirements |
| Post-market surveillance | PMS, PMCF, vigilance, trend reporting and periodic reporting requirements apply under the EU MDR | GB PMS requirements apply under the UK MDR, including strengthened post-market surveillance requirements introduced in 2025 |
| Market surveillance | Undertaken by competent authorities across EU Member States | Undertaken by the MHRA |
| Regulatory development | EU MDR is established legislation but continues to be supplemented by implementing legislation and guidance | UK medical device regulation is undergoing a programme of reform, with further chan |
The Key Point for Manufacturers
Compliance with the EU MDR does not automatically mean that a manufacturer complies with the UK MDR, and UK MDR compliance does not provide automatic access to the EU market.
There is, however, significant overlap between the two systems. Manufacturers operating in both markets can often use the same underlying quality management system, risk management processes, clinical evidence and substantial parts of their technical documentation.
The important distinction is that these common elements must be assessed against the legal requirements applicable in each market. Manufacturers should therefore maintain a coordinated regulatory strategy while clearly identifying EU-specific and UK-specific requirements, documentation and responsibilities.
This approach can reduce unnecessary duplication while ensuring that compliance with one regulatory framework is not incorrectly assumed to demonstrate compliance with the other.
Can a CE-Marked Medical Device Be Sold in Great Britain?
Yes. CE-marked medical devices that meet the applicable eligibility requirements can currently be placed on the Great Britain market under transitional recognition arrangements.
This means manufacturers do not necessarily need to obtain UKCA marking before supplying a medical device in England, Scotland or Wales.
However, the period for which a CE-marked device can continue to be placed on the Great Britain market depends on the regulatory route under which the device is CE marked.
Current Recognition of CE-Marked Medical Devices in Great Britain
Under the current transitional arrangements:
- General medical devices compliant with the EU MDR can be placed on the Great Britain market until 30 June 2030.
- General medical devices compliant with the former EU Medical Devices Directive (MDD) or Active Implantable Medical Devices Directive (AIMDD), with a valid certificate and meeting the relevant EU transitional requirements, can generally be placed on the Great Britain market until the sooner of 30 June 2028 or expiry of the applicable certificate.
- Different transitional arrangements apply to in vitro diagnostic medical devices.
These arrangements allow manufacturers to continue using eligible CE certification for access to the Great Britain market while the UK develops its future medical device regulatory framework.
Importantly, recognition of CE marking does not remove the manufacturer’s UK-specific regulatory obligations.
A manufacturer placing a CE-marked device on the Great Britain market must still meet applicable UK requirements, including:
- Registering the device with the MHRA before it is placed on the Great Britain market.
- Appointing a UK Responsible Person where the manufacturer is established outside the UK.
- Meeting applicable UK post-market surveillance and vigilance requirements.
- Ensuring that labelling and accompanying information meet applicable UK requirements.
Manufacturers should therefore distinguish between the conformity assessment route used to demonstrate device compliance and the additional regulatory obligations associated with placing that device on the Great Britain market.
Is UKCA Marking Mandatory?
UKCA remains the domestic conformity assessment and product marking route available for medical devices in Great Britain.
Where third-party conformity assessment is required for UKCA marking, the assessment must be undertaken by an appropriately designated UK Approved Body.
However, because eligible CE-marked devices continue to be recognised in Great Britain, manufacturers should assess whether obtaining UKCA marking is currently necessary for their particular device and commercial strategy.
The UK’s approach to recognising international regulatory approvals is also continuing to develop. Manufacturers should therefore monitor MHRA and UK Government regulatory changes rather than assuming that the current transitional deadlines represent the final long-term market access framework.
A Practical EU MDR and UK MDR Compliance Strategy
Manufacturers planning to place the same medical device on both the European Union and Great Britain markets should avoid treating EU MDR and UK MDR compliance as two completely separate projects.
There is significant overlap between the two regulatory systems, particularly in areas such as quality management, risk management, clinical evidence, technical documentation and post-market activities. However, manufacturers must still identify and address the requirements that are specific to each market.
A practical dual-market compliance strategy can follow the steps below.
Step 1: Confirm the Intended Purpose and Device Classification
Clearly define the device’s intended purpose, indications, target population and operating principles.
The device must then be classified under the applicable regulatory framework. Although both systems currently use Classes I, IIa, IIb and III for general medical devices, manufacturers should assess classification against the rules applicable in each market rather than assuming the result will always be identical.
Step 2: Determine the Appropriate Conformity Assessment Route
The required conformity assessment route depends on the device classification and characteristics.
Under the EU MDR, devices requiring third-party conformity assessment must use an appropriately designated EU Notified Body.
For the UKCA route in Great Britain, devices requiring third-party conformity assessment must use a UK Approved Body.
Manufacturers using the current CE recognition arrangements for Great Britain may instead rely on an eligible CE-marked device, subject to the applicable transitional requirements.
Step 3: Establish a Quality Management System
Manufacturers should establish and maintain a quality management system appropriate to the device and regulatory route.
ISO 13485 provides an internationally recognised framework for medical device quality management systems and can provide a common foundation for manufacturers operating in both the EU and UK markets.
However, manufacturers should ensure their QMS also addresses any specific regulatory requirements applicable in each jurisdiction.
Need an Introduction to ISO 13485?
ISO 13485 provides the internationally recognised framework for medical device quality management systems and can support manufacturers operating across both the EU and UK markets. For a complete overview of the standard, including QMS requirements, certification, implementation and regulatory relevance, read our Complete Guide to ISO 13485.
Step 4: Prepare the Technical Documentation
Technical documentation should demonstrate that the device meets the applicable safety, performance and regulatory requirements.
A significant proportion of the underlying evidence may be shared between EU and UK submissions, including:
- Device descriptions and specifications
- Design and manufacturing information
- Risk management documentation
- Verification and validation evidence
- Biological evaluation, where applicable
- Clinical evidence
- Software documentation, where applicable
- Usability engineering documentation
- Labelling and instructions for use
- Post-market surveillance documentation
Manufacturers should nevertheless perform a regulatory gap assessment to identify EU-specific and UK-specific documentation requirements.
Need Help Understanding Medical Device Technical Documentation?
Technical documentation provides the evidence that a medical device meets the applicable regulatory requirements. For a practical guide covering technical file structure, required documentation, risk management, clinical evidence, verification and validation, labelling and post-market documentation, read our Complete Guide to Medical Device Technical Files.
Step 5: Establish Clinical Evidence
Manufacturers must hold sufficient clinical evidence to support the safety and performance of the device for its intended purpose.
For the EU market, clinical evaluation must meet the applicable requirements of the EU MDR, including Article 61 and Annex XIV.
For Great Britain, manufacturers must demonstrate compliance with the applicable clinical evidence requirements of the UK MDR.
A well-developed clinical evidence strategy can often support both markets, provided the evidence is assessed against the requirements of each regulatory framework.
Need an Introduction to Medical Device Clinical Evaluation?
Clinical evaluation is a fundamental part of demonstrating the safety and performance of a medical device. For a complete overview of clinical evaluation requirements, clinical evidence, Clinical Evaluation Plans (CEPs), Clinical Evaluation Reports (CERs), literature review and ongoing evaluation, read our Complete Guide to Medical Device Clinical Evaluation.
Step 6: Appoint the Required Regulatory Representatives
Manufacturers established outside the European Union generally need to appoint an EU Authorised Representative before placing devices on the EU market.
Manufacturers established outside the UK must appoint a UK Responsible Person before placing devices on the Great Britain market.
These are separate regulatory roles. A manufacturer supplying both markets may therefore require both an EU Authorised Representative and a UK Responsible Person.
Need a UK Responsible Person?
Medical device manufacturers established outside the UK must appoint a UK Responsible Person before placing their devices on the Great Britain market. Learn more about the role, manufacturer responsibilities, MHRA registration and how Patient Guard can support your UK market access through our UK Responsible Person Service.
Need an EU Authorised Representative?
Medical device manufacturers established outside the EU must generally appoint an EU Authorised Representative before placing their devices on the European Union market. Learn more about the role, regulatory responsibilities and how Patient Guard can support your EU market access through our EU Authorised Representative Service.
Step 7: Complete Device Registration and Market Access Requirements
Before placing a device on the market, manufacturers must complete the applicable registration and market access requirements.
In Great Britain, medical devices must be registered with the MHRA in accordance with the applicable UK requirements.
In the EU, manufacturers and other economic operators must comply with the applicable EU MDR registration requirements, including the relevant EUDAMED obligations as they become mandatory.
Step 8: Maintain Post-Market Compliance
Regulatory compliance does not end when a device is placed on the market.
Manufacturers must maintain appropriate systems for post-market surveillance, vigilance, complaint handling, corrective and preventive action and, where applicable, post-market clinical follow-up.
Post-market information should also feed back into risk management, clinical evaluation and the manufacturer’s wider quality management system.
For manufacturers operating in both markets, these activities can often be managed through an integrated global post-market system, provided the different EU and UK reporting and regulatory requirements are clearly identified and followed.
Need an Introduction to Medical Device Post-Market Surveillance?
Post-market surveillance is an ongoing regulatory requirement after a medical device is placed on the market. For a complete overview of PMS systems, PMS Plans, PMS Reports, PSURs, vigilance, trend reporting, PMCF and the requirements under the EU MDR, EU IVDR and UK MDR, read our Complete Guide to Medical Device Post-Market Surveillance.
Can You Use the Same Technical Documentation for the EU and UK?
Manufacturers do not necessarily need to create two completely separate sets of technical documentation for the European Union and Great Britain.
Much of the underlying evidence used to demonstrate the safety and performance of a medical device can support compliance in both markets. This can include device specifications, design and manufacturing information, risk management, clinical evidence, verification and validation, biological evaluation, software documentation and post-market information.
However, the EU MDR and UK MDR are separate legal frameworks. A technical file prepared solely against the EU MDR should therefore not automatically be considered a UK MDR technical file without assessing it against the applicable Great Britain requirements.
Where Can the Documentation Be Shared?
Manufacturers can often maintain a common core of technical documentation covering:
- Device description and specifications
- Intended purpose and indications
- Design and manufacturing information
- Risk management documentation
- Verification and validation
- Biological safety and biocompatibility
- Electrical safety and electromagnetic compatibility, where applicable
- Software verification and validation, where applicable
- Usability engineering
- Clinical evidence
- Sterilisation and packaging validation, where applicable
- Post-market surveillance data
Using a common evidence base can significantly reduce duplication when accessing both markets.
Where Are Market-Specific Differences Needed?
Certain parts of the regulatory documentation may need to be adapted or maintained separately for each market.
For example, manufacturers may need to account for differences in:
- Applicable regulatory requirements
- EU MDR GSPRs and UK MDR Essential Requirements
- Conformity assessment routes
- CE and UKCA marking
- EU Declaration of Conformity and UK Declaration of Conformity
- EU Authorised Representative and UK Responsible Person details
- Device registration requirements
- Labelling requirements
- Post-market surveillance and vigilance reporting
- References to applicable legislation and regulatory authorities
Manufacturers should therefore consider maintaining a controlled core technical documentation set supported by market-specific regulatory documents or annexes.
Use a Regulatory Gap Assessment
Where an existing EU MDR technical file is being used to support entry into the Great Britain market — or UK documentation is being adapted for EU MDR compliance — a regulatory gap assessment should be performed.
The assessment should identify which evidence can be reused, which documents require amendment and where additional evidence or documentation is required.
This approach is generally more efficient than rebuilding the technical documentation from the beginning while still ensuring that the requirements of each regulatory framework are independently addressed.
The same principle applies to the manufacturer’s quality management system. A single integrated QMS can support both EU and UK operations, but it must incorporate the regulatory requirements and responsibilities applicable to each market.
EU Authorised Representative vs UK Responsible Person
Manufacturers based outside the markets in which they intend to sell their medical devices may need to appoint a local regulatory representative.
For the European Union, this role is performed by an EU Authorised Representative. For Great Britain, the equivalent regulatory role is the UK Responsible Person.
Although the roles share some similarities, they arise under different legislation and should not be treated as interchangeable.
EU Authorised Representative
Under the EU MDR, a manufacturer established outside the European Union must generally designate a sole EU Authorised Representative for a device of the same generic device group.
The Authorised Representative is established within the EU and acts on the basis of a written mandate from the manufacturer. Its regulatory obligations include tasks such as verifying certain manufacturer documentation and registrations, cooperating with competent authorities and forwarding regulatory requests to the manufacturer.
The EU Authorised Representative’s name and address must also appear on the device labelling in accordance with the applicable EU MDR requirements.
UK Responsible Person
A manufacturer based outside the UK that wishes to place a medical device on the Great Britain market must appoint a UK Responsible Person.
The UK Responsible Person acts on behalf of the manufacturer in relation to specified obligations under the UK MDR and is responsible for registering the manufacturer’s devices with the MHRA.
The UK Responsible Person must have a registered place of business in the UK, and its name and address must be included on product labelling where required by the applicable UK rules.
Do You Need Both?
A non-EU and non-UK manufacturer supplying both the European Union and Great Britain will generally require both an EU Authorised Representative and a UK Responsible Person.
Appointing an EU Authorised Representative does not satisfy the UK Responsible Person requirement, and appointing a UK Responsible Person does not provide representation within the European Union.
Manufacturers should therefore establish clear written agreements defining each representative’s responsibilities and ensure that regulatory communication, vigilance, registration and post-market processes correctly distinguish between the two markets.
For manufacturers operating internationally, using coordinated EU and UK regulatory representation can help simplify communication and maintain consistency across both market access strategies.
Post-Market Surveillance: EU MDR vs UK MDR
Manufacturers must continue to monitor the safety and performance of their medical devices after they have been placed on the market. Both the EU MDR and UK MDR require post-market surveillance, but manufacturers need to comply with the specific requirements and reporting processes applicable in each market.
Post-Market Surveillance Under the EU MDR
The EU MDR significantly strengthened post-market surveillance requirements and requires manufacturers to establish a proactive and systematic PMS system proportionate to the risk and type of device.
Depending on the device and its classification, manufacturers may need to maintain:
- A Post-Market Surveillance Plan
- A Post-Market Surveillance Report (PMSR) for Class I devices
- A Periodic Safety Update Report (PSUR) for Class IIa, IIb and III devices
- Post-Market Clinical Follow-up (PMCF), where applicable
- Vigilance and serious incident reporting processes
- Trend reporting
- Processes for field safety corrective actions
Information gathered through PMS must feed back into other parts of the manufacturer’s regulatory system, including risk management, clinical evaluation, labelling and technical documentation.
Post-Market Surveillance Under the UK MDR
Great Britain introduced strengthened post-market surveillance requirements through the Medical Devices (Post-market Surveillance Requirements) (Amendment) Regulations 2024, which came into force on 16 June 2025.
The updated requirements apply to medical devices placed on the Great Britain market and establish more detailed obligations for manufacturers covering areas such as:
- PMS systems and plans
- Collection and analysis of post-market information
- Preventive and corrective actions
- Serious incident reporting
- Field safety corrective actions
- Trend reporting
- Periodic reporting for applicable devices
- Documentation and retention of PMS information
The reforms bring greater structure and clarity to post-market surveillance in Great Britain, although manufacturers should not assume that the UK requirements are identical to those of the EU MDR.
Managing PMS Across Both Markets
Manufacturers supplying devices in both the EU and Great Britain can often operate a common underlying post-market surveillance system.
Complaints, adverse events, trend data, literature, customer feedback and other post-market information can be collected and evaluated through an integrated process.
However, the system must identify the regulatory requirements applicable to each jurisdiction. In particular, manufacturers should ensure that:
- Incidents are assessed against the correct EU and UK reporting criteria.
- Applicable reporting deadlines are followed.
- Reports are submitted to the appropriate regulatory authorities and systems.
- EU and UK regulatory representatives are involved where required.
- Market-specific PMS documentation is maintained where necessary.
- Corrective actions are implemented consistently across affected markets.
A coordinated PMS system can therefore reduce duplication, but the manufacturer remains responsible for demonstrating compliance with the applicable requirements in each market.
Post-market surveillance should also be viewed as part of a continuous regulatory lifecycle. Information generated after market launch should be used to update risk management, clinical evaluation and other relevant technical documentation throughout the lifetime of the device.
What Is Changing Under the Future UK Medical Device Regulations?
The regulatory framework for medical devices in Great Britain is undergoing significant reform. Rather than replacing the UK MDR 2002 with a single new regulation at one time, the Government is implementing changes incrementally through amendments to the existing legislation.
The first major part of this programme has already taken effect. Strengthened post-market surveillance requirements became applicable in Great Britain on 16 June 2025.
Further reforms are being developed for the pre-market regulatory framework.
Proposed Pre-Market Requirements
In May 2026, the MHRA published draft Medical Devices (Amendment) Regulations 2026 setting out proposed changes to the Great Britain pre-market framework.
The proposed reforms include measures intended to:
- Introduce an international reliance framework for certain medical devices already approved in recognised jurisdictions.
- Make Unique Device Identification (UDI) requirements mandatory.
- Bring Great Britain’s Essential Requirements into closer alignment with international best practice.
- Strengthen technical documentation retention requirements.
- Introduce additional requirements for implantable medical devices, including implant cards.
- Strengthen requirements relating to custom-made devices.
- Require manufacturers to ensure device claims are consistent with the stated intended purpose.
- Introduce changes affecting the regulation and classification of IVD medical devices.
Until these changes are enacted and brought into force, manufacturers must continue to comply with the regulatory requirements currently applicable under the UK MDR 2002.
Future Recognition of CE-Marked Devices
The future role of CE marking in Great Britain is also under review.
In February 2026, the MHRA consulted on proposals that included indefinite recognition in Great Britain of medical devices compliant with the EU MDR and EU IVDR.
The consultation also considered extending recognition arrangements for eligible devices certified under the former EU medical device directives to align more closely with EU transition timelines.
These proposals could significantly affect the long-term relationship between CE marking and UKCA marking. However, manufacturers should distinguish between proposals and requirements that have already entered into law.
Until any further legislative changes take effect, the existing transitional arrangements for recognition of eligible CE-marked medical devices remain applicable.
International Recognition
Another important part of the future framework is the proposed use of regulatory approvals from other jurisdictions.
The Government has been developing an international reliance route intended to allow Great Britain to make greater use of approvals from comparable regulators, reducing unnecessary duplication while maintaining UK regulatory oversight.
This could provide additional routes to the Great Britain market alongside UKCA marking and recognition of eligible CE-marked devices.
Further Regulatory Reform
The UK’s medical device framework may continue to evolve beyond the current programme of amendments.
In September 2026, the Government proposed new legislative powers that could support the future development of an MHRA medical device licensing regime for devices entering Great Britain through a domestic route.
Any such licensing system would require further policy development and implementation. The existing UKCA framework remains in place while these proposals are considered.
What Should Manufacturers Do Now?
Manufacturers should not delay current compliance activities in anticipation of future regulatory changes.
Instead, manufacturers should:
- Comply with the UK MDR requirements currently in force.
- Ensure compliance with the strengthened GB post-market surveillance requirements.
- Confirm whether their CE-marked devices qualify for the current Great Britain transitional arrangements.
- Maintain MHRA device registrations.
- Maintain an appropriately appointed UK Responsible Person where required.
- Monitor implementation of the proposed pre-market reforms.
- Assess how future international recognition and CE recognition arrangements could affect their longer-term Great Britain market access strategy.
The direction of travel is towards a more modern and internationally aligned Great Britain regulatory system, but manufacturers should base compliance decisions on requirements that are legally in force rather than proposed future measures.
Want to Understand the Future of UK Medical Device Regulation?
The UK medical device regulatory framework is undergoing significant reform, including proposed changes to market access, international reliance, UDI, technical documentation, IVD classification and other regulatory requirements. For a detailed overview of the reforms and what manufacturers should be preparing for, read our MHRA 2026 Regulatory Roadmap Explained.
Building an Efficient EU and UK Medical Device Compliance Strategy
Manufacturers targeting both the European Union and Great Britain should develop a coordinated regulatory strategy rather than managing each market entirely independently.
Although the EU MDR and UK MDR are separate legal frameworks, many of the systems, processes and evidence needed to demonstrate compliance can be shared. The objective should be to create a common regulatory foundation while clearly controlling the requirements that differ between the two markets.
Build a Common Regulatory Foundation
Where appropriate, manufacturers can establish common processes for:
- Quality management under ISO 13485
- Risk management under ISO 14971
- Design and development controls
- Clinical evidence generation
- Biological evaluation
- Verification and validation
- Software lifecycle processes
- Usability engineering
- Supplier management
- Complaint handling
- Post-market surveillance
- Corrective and preventive action
This can significantly reduce duplication while supporting consistent device safety and performance across markets.
Identify Market-Specific Requirements
The common regulatory foundation should then be supplemented by requirements specific to the EU or Great Britain.
These may include:
- Applicable legislation and conformity requirements
- CE or UKCA conformity assessment routes
- Notified Body or UK Approved Body involvement
- EU Authorised Representative or UK Responsible Person
- Declarations of Conformity
- Device registration
- Labelling requirements
- Regulatory reporting
- Post-market documentation
- Communication with regulatory authorities
A regulatory requirements matrix or gap assessment can be particularly useful for identifying where common documentation can be used and where jurisdiction-specific controls are required.
Consider Market Access Early
EU and UK regulatory strategy should be considered during product development rather than after the technical documentation has been completed.
Early planning allows manufacturers to identify the evidence, testing, clinical data and quality system requirements needed for both markets before significant design decisions have been finalised.
This is particularly important where differences in classification, conformity assessment or future Great Britain requirements could affect the regulatory pathway.
Maintain Compliance Throughout the Device Lifecycle
Market access is only the beginning of regulatory compliance.
Manufacturers must continue to monitor regulatory changes, maintain technical documentation, review clinical and risk management information, conduct post-market surveillance and implement corrective actions throughout the device lifecycle.
For manufacturers operating across both the EU and Great Britain, regulatory change management should therefore include monitoring developments in both jurisdictions and assessing whether changes affect existing devices, documentation, registrations or market access routes.
A well-designed dual-market strategy allows manufacturers to use common evidence and regulatory systems efficiently while maintaining clear compliance with the requirements applicable in each jurisdiction.
How Patient Guard Can Help with EU and UK Medical Device Compliance
Navigating the EU MDR and UK MDR can be complex, particularly for manufacturers seeking to place the same medical device on both markets.
Patient Guard supports medical device manufacturers throughout the regulatory lifecycle, helping identify where EU and UK requirements can be aligned and where separate regulatory activities are required.
Our medical device regulatory specialists can support manufacturers with:
- EU MDR and UK MDR regulatory strategy
- Medical device classification
- Regulatory gap assessments
- Technical documentation and technical file preparation
- Clinical Evaluation Plans (CEPs) and Clinical Evaluation Reports (CERs)
- Biological Evaluation Plans (BEPs) and Biological Evaluation Reports (BERs)
- ISO 14971 risk management
- ISO 13485 quality management system implementation
- Post-market surveillance and PMCF
- CE and UKCA conformity assessment preparation
- Notified Body and UK Approved Body preparation and support
- EU Authorised Representative services
- UK Responsible Person services
- MHRA medical device registration
- Labelling and regulatory documentation reviews
- Ongoing regulatory and quality assurance support
Supporting Access to Both Markets
For manufacturers targeting both the European Union and Great Britain, we can review your existing regulatory documentation and identify what can be used across both markets and what needs to be adapted.
This can help avoid unnecessary duplication while ensuring that market-specific requirements are properly addressed.
Whether you are developing a new medical device, transitioning an existing product to the EU MDR, entering the Great Britain market or maintaining an established device across both jurisdictions, Patient Guard can provide regulatory support appropriate to your device, classification and intended markets.
Contact Patient Guard to discuss your EU and UK medical device regulatory requirements and develop a practical route to market.
Frequently Asked Questions Relating to EU MDR and UK MDR
No. The EU MDR (Regulation (EU) 2017/745) and UK Medical Devices Regulations 2002 are separate regulatory frameworks.
Although they share many principles, there are important differences in areas such as conformity assessment, regulatory representation, registration, product marking and post-market requirements. Manufacturers should assess compliance separately for each market.
The EU MDR does not apply in Great Britain — England, Scotland and Wales — where medical devices are regulated under the UK MDR 2002.
The position is different in Northern Ireland. Under the Windsor Framework, relevant EU medical device legislation continues to apply to medical devices placed on the Northern Ireland market.
Yes. Eligible CE-marked medical devices can currently be placed on the Great Britain market under transitional recognition arrangements.
The applicable recognition period depends on the regulatory route under which the device has been CE marked. Manufacturers must also continue to meet applicable UK requirements, including MHRA registration, UK Responsible Person requirements and post-market obligations.
Not necessarily. Eligible CE-marked devices continue to be recognised in Great Britain under the current transitional arrangements, so manufacturers do not automatically need to obtain UKCA marking simply to access the GB market.
UKCA remains the domestic conformity assessment route for medical devices in Great Britain. Manufacturers should assess the most appropriate route based on their device, existing certification and longer-term market access strategy.
Much of the underlying technical documentation and supporting evidence can potentially be used for both markets. However, an EU MDR technical file should not automatically be assumed to demonstrate compliance with the UK MDR.
Manufacturers should perform a gap assessment against the applicable requirements in each jurisdiction and maintain appropriate market-specific documentation where necessary.
A manufacturer established outside both the EU and UK that places medical devices on both markets will generally require both.
The EU Authorised Representative fulfils regulatory responsibilities within the European Union, while the UK Responsible Person represents an overseas manufacturer in relation to its Great Britain regulatory obligations. The two roles are separate and are not interchangeable.
Yes. Great Britain’s medical device regulatory framework is undergoing a programme of reform.
Strengthened post-market surveillance requirements have already applied since 16 June 2025, while further reforms to areas such as pre-market requirements, international recognition, device identification and other regulatory requirements are being developed.
Manufacturers should continue to comply with the requirements currently in force while monitoring MHRA and UK Government announcements for future changes.
References
This guide is based on current UK and European Union legislation and official regulatory guidance relating to medical devices, including the EU Medical Device Regulation (EU MDR), UK Medical Devices Regulations 2002, CE and UKCA marking, market access, post-market surveillance, EUDAMED and the ongoing reform of the Great Britain medical device regulatory framework.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 on Medical Devices (EU MDR) | Establishes the EU regulatory framework for medical devices, including classification, conformity assessment, technical documentation, clinical evaluation, economic operators, CE marking, post-market surveillance and vigilance. |
| UK Government | Medical Devices Regulations 2002 (SI 2002 No. 618) | Provides the principal legislative framework governing medical devices in Great Britain. The Regulations have been amended following the UK's withdrawal from the EU and continue to form the basis of the GB medical device regulatory system. |
| MHRA | Regulating Medical Devices in the UK | Provides the MHRA's principal guidance for manufacturers placing medical devices on the UK market, including UKCA marking, CE marking, MHRA registration, UK Responsible Persons, conformity assessment and the different requirements applying in Great Britain and Northern Ireland. |
| MHRA | Timelines for Acceptance of CE Marked Medical Devices in Great Britain | Sets out the current transitional arrangements allowing eligible CE-marked medical devices to continue to be placed on the Great Britain market, including the applicable 2028 and 2030 deadlines. |
| UK Government | Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 | Amends the UK MDR 2002 to introduce strengthened post-market surveillance requirements for medical devices in Great Britain, including PMS systems, vigilance, serious incident reporting, trend reporting and corrective actions. |
| MHRA | Medical Devices: Post-Market Surveillance Requirements | Provides official MHRA guidance on the strengthened Great Britain post-market surveillance requirements that came into force on 16 June 2025. |
| MHRA | Implementation of the Future Regulations | Sets out the Government and MHRA approach to the phased reform of the Great Britain medical device regulatory framework, including post-market reforms, proposed pre-market requirements, international reliance and future regulatory enhancements. |
| MHRA | Response to International Reliance, UKCA Marking and In Vitro Diagnostic Devices Consultation Proposal | Explains the Government's intended direction for future GB market access, including international reliance, Unique Device Identification requirements and planned changes to the domestic regulatory framework. |
| European Commission | European Database on Medical Devices (EUDAMED) – Overview | Provides current European Commission information on EUDAMED and its implementation. The Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance modules became mandatory from 28 May 2026. |
| MHRA | MHRA Regulatory Reform Amendments Tabled in Government's Health Bill | Provides the latest information on proposed legislative changes announced in September 2026, including powers intended to support regulatory reform and the potential future development of an MHRA medical device licensing regime. |
Medical device regulation in Great Britain is continuing to evolve. Manufacturers should distinguish between requirements currently in force and proposed future reforms, and should monitor MHRA and UK Government publications when planning long-term UK market access.
Patient Guards Recent Posts
FDA Medical Device Classification: Class I, Class II and Class III Explained
Does your medical device require FDA 510(k) clearance? This step-by-step guide explains the 510(k) process, substantial equivalence, predicate devices, testing, eSTAR submissions, FDA review and what manufacturers need to do after clearance.
FDA 510(k) Clearance: A Step-by-Step Guide for Medical Device Manufacturers
Does your medical device require FDA 510(k) clearance? This step-by-step guide explains the 510(k) process, substantial equivalence, predicate devices, testing, eSTAR submissions, FDA review and what manufacturers need to do after clearance.
FDA Medical Device Regulations: A Complete Guide for Manufacturers
Planning to place a medical device on the US market? This complete guide explains FDA medical device regulations, including device classification, 510(k), De Novo and PMA pathways, QMSR and ISO 13485, establishment registration, device listing, U.S. Agent requirements, UDI and post-market obligations.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
